Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based Sareum Holdings has extended its agreement with Genentech, for a further six months following its initial agreement announced in November 2006. Financial terms of the agreement were not disclosed.
Subscribe to our email newsletter
Under the terms of this agreement, Sareum will continue to apply its skills in high-throughput protein expression, purification and structure determination on drug discovery targets designated by Genentech. In return, Sareum will receive research fees and may receive specific success-dependent milestone payments.
Dr Tim Mitchell, Sareum’s CEO, said: “Successfully delivering on relationships with leading companies such as Genentech is a key component of our business strategy and an outstanding validation of Sareum’s technology and expertise. We are very pleased to have supported Genentech’s programs over the last 12 months, and look forward to continuing this important relationship.”